Sugi Predict

Sugi Predict / Compounds / SCHEMBL560143

SCHEMBL560143

SCHEMBL560143

CC(=O)Nc1cc(C(=O)O)ccc1C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.57
▸ NPC1 O15118 4/20 0.57
▸ RAB9A P51151 3/20 0.57
▸ SMN1; SMN2 Q16637 2/20 0.57
▸ SELL P14151 2/20 0.56
▸ SELP P16109 2/20 0.56
▸ ALDH1A1 P00352 6/20 0.55
▸ KDM4E B2RXH2 2/20 0.55
▸ CASR P41180 1/20 0.55
▸ NEU3 Q9UQ49 1/20 0.54
▸ MEN1 O00255 4/20 0.54
▸ KMT2A Q03164 4/20 0.54
▸ MAPT P10636 2/20 0.54
▸ SELE P16581 1/20 0.54
▸ GAA P10253 1/20 0.54
▸ MAPK1 P28482 1/20 0.54
▸ ADRB2 P07550 1/20 0.53
▸ HPGD P15428 1/20 0.53
▸ LMNA P02545 1/20 0.52
▸ ALOX12 P18054 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13100053 0.87 NPC1 (0.56) NPC1RAB9ASMN1; SMN2ALDH1A1MEN1
SCHEMBL30508348 0.87 NPC1 (0.56) NPC1RAB9ASMN1; SMN2ALDH1A1MEN1
SCHEMBL18757940 0.86 ALDH1A1 (0.56) L3MBTL1NPC1RAB9ASMN1; SMN2SELL
SCHEMBL3586872 0.85 NEU3 (0.58) NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL3891611 0.85 NPC1 (0.64) NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL28384105 0.84 NPC1 (0.54) L3MBTL1NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL14339916 0.83 L3MBTL1 (0.52) L3MBTL1NPC1RAB9ASMN1; SMN2SELL
SCHEMBL2558622 0.83 SELL (0.62) L3MBTL1NPC1RAB9ASELLSELP
SCHEMBL29707260 0.82 CASR (0.56) L3MBTL1NPC1RAB9ASMN1; SMN2SELL
SCHEMBL9436316 0.82 ALDH1A1 (0.69) L3MBTL1NPC1RAB9ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111039932-B High-yield synthesis method of radatinib 安徽峆一药业股份有限公司 2023-09-12 — — CN claimed
CN-110872279-B High-yield synthesis method of nilotinib 安徽峆一药业股份有限公司 2023-09-08 — — CN claimed
CN-111039932-A High-yield synthesis method of ladostinib 安徽峆一药业股份有限公司 2020-04-21 — — CN claimed
CN-110872279-A High-yield synthesis method of nilotinib 安徽峆一药业股份有限公司 2020-03-10 — — CN claimed
US-20260102406-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY NEUPHARMA INC (US) 2026-04-16 — — US disclosed
EP-3508204-B1 QUINAZOLIN-8-YL DERIVATIVES FOR USE IN METHODS OF TREATING MELANOMA, NON-SMALL CELL LUNG CANCER, THYROID CANCER, OVARIAN CANCER, OR COLON CANCER NEUPHARMA INC (US) 2026-02-11 — — EP disclosed
US-12403145-B2 Substituted quinazolines for inhibiting kinase activity NEUPHARMA, INC (US) 2025-09-02 — — US disclosed
US-20240197752-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY NEUPHARMA INC 2024-06-20 — — US disclosed
US-11865120-B2 Substituted quinazolines for inhibiting kinase activity NEUPHARMA, INC. (US) 2024-01-09 — — US disclosed
CN-111039932-B High-yield synthesis method of radatinib 安徽峆一药业股份有限公司 2023-09-12 — — CN disclosed
CN-111039932-B High-yield synthesis method of radatinib 安徽峆一药业股份有限公司 2023-09-12 — — CN disclosed
CN-110872279-B High-yield synthesis method of nilotinib 安徽峆一药业股份有限公司 2023-09-08 — — CN disclosed
WO-2004074279-A1 METHODS OF MAKING 6-[(4,5-DIHYDRO-1H-IMIDAZOL-2-YL)AMINO-]-7-METHYL-1H-BENZIMIDAZOLE-4-CARBONITRILE AND ITS PREFERRED SALT FORM THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) 2004-09-02 — — WO disclosed
US-20040167194-A1 Methods of making 6-[(4,5-Dihydro-1H-imidazol-2-yl)amino-]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt form THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA 2004-08-26 — — US disclosed
US-20040082079-A1 Low affinity screening method GRAFFINITY PHARMACEUTICALS AG. (DE) 2004-04-29 — — US disclosed
EP-1360489-A1 LOW AFFINITY SCREENING METHOD Graffinity Pharmaceuticals Aktiengesellschaft (DE) 2003-11-12 — — EP disclosed
WO-2002063299-A1 LOW AFFINITY SCREENING METHOD GRAFFINITY PHARMACEUTICALS AG (DE) 2002-08-15 — — WO disclosed
EP-1091958-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2001-04-18 — — EP disclosed
WO-2000001692-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2000-01-13 — — WO disclosed
US-5444038-A Arylindazoles and their use as herbicides ZENECA LIMITED (GB) 1995-08-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167194-A1 Methods of making 6-[(4,5-Dihydro-1H-imidazol-2-yl)amino-]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt form AGTR2, ALDH1A2, REN L3MBTL1 4534/4885NPC1 3395/4885RAB9A 4080/4885
US-20240197752-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY DCK, ABL1, MAP4K2 L3MBTL1 1807/4885NPC1 3185/4885RAB9A 1145/4885
US-11865120-B2 Substituted quinazolines for inhibiting kinase activity DCK, ABL1, MAP4K2 L3MBTL1 1807/4885NPC1 3185/4885RAB9A 1145/4885
US-12403145-B2 Substituted quinazolines for inhibiting kinase activity DCK, ABL1, MAP4K2 L3MBTL1 1807/4885NPC1 3185/4885RAB9A 1145/4885
US-20260102406-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY BRAF, TTK, MAP4K2 L3MBTL1 4835/4885NPC1 3197/4885RAB9A 1110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.